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INTRODUCTION
Acute myeloid leukemia (AML) represents a group of hema-
tological malignancies characterized by uncontrolled hema-
topoietic cell proliferation, decreased apoptosis, blocked dif-
ferentiation hematopoiesis, and an accumulation of clonal 
myeloid progenitor cells that do not differentiate normally.1,2 
While 5-year overall survival (OS) rates range from 40% to 50% 
in younger (<50 years) AML patients, the 5-year OS rate for old-
er patients (>70 years) is only 5 to 10%.3,4 Although 60–80% of 
adult patients treated first with intensive induction chemother-
apy achieve complete remission, more than 50% of patients will 
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show primary refractory or relapsed (R/R) disease,1 which is as-
sociated with extremely poor prognosis, and treatment of R/R 
or older patients with AML remains highly challenging and 
controversial. 
It has long been argued that overcoming the differentiation 
block in AML would improve treatment regimens. For exam-
ple, all-trans retinoic acid (ATRA), a derivative of vitamin A 
that affects cellular development, including hematopoiesis, 
especially granulocyte differentiation,5 has been used to treat 
acute promyelocytic leukemia (APL), in which 99% of cases 
display translocation t(15;17) with the consequent chimeric 
protein PML-RARα.6 ATRA causes APL cells displaying PML-
RARα to differentiate into “abnormal” neutrophils and decreas-
es the risk of relapse within 2 years by more than 50%.7 However, 
for other subtypes of AML, identification of practical means of 
differentiation therapy has proven to be more challenging.
Aberrant differentiation is often, partly at least, handled by 
epigenetic deregulation.8 Research has shown that AML pa-
tients carry mutations in genes involved in DNA methylation 
and modification of histone marks; for example, somatic mu-
tations in the isocitrate dehydrogenase 2 (IDH2) gene occur-
ring at conserved arginine residues (R140 and R172)9,10 could 
affect cellular metabolism, epigenetic regulation, redox states, 
and DNA repair. Mutations in genes encoding enzymes impor-
tant in epigenetic regulation have been reported in several types 
of malignancies, including >80% of low-grade gliomas and sec-
ondary glioblastomas,11 ~60% of chondrosarcomas,12 ~20% of 
intrahepatic cholangiocarcinomas,13 and ~10% of AMLs.9,10 
These mutant proteins have neomorphic enzyme activity lead-
ing to R-2-hydroxyglutarate (2-HG) accumulation. The result-
ing 2-HG accumulation competitively inhibits α-ketoglutarate-
dependent enzymes,10,14,15 resulting in DNA methylation,14 
increased repressive histone methylation,16 and damaged he-
matopoietic differentiation. Because the neomorphic produc-
tion of 2-HG is a gain of function that is exclusive to mutant 
IDH1/2 enzymes, researchers noted that these genetic changes 
may be encouraging targets for personalized anti-cancer thera-
py with small-molecule inhibitors.17 Indeed, enasidenib (AG-
221, IDH2-mutant inhibitor) was approved by the FDA for 
treatment for R/R IDH2-mutant AML patient as a first-in-class 
inhibitor.17,18 Stein, et al.18 investigated clinical responses in pa-
tients with R/R AML (n=176), and treatment with enasidenib 
elicited an overall response in 40.3% of patients and complete 
remission in about 50%. The median OS of the patients achiev-
ing complete remission was 19.7 months. In spite of the com-
paratively high response rates, not all patients experience clini-
cal benefit. Therefore, differentiation-based IDH2 inhibition 
may need to be combined with other treatment modalities.19 
ATRA has been used successfully in the treatment of APL. 
However, non-APL patients do not show comparable sensitivity 
to ATRA. Recent data, however, has shown that de novo AML 
patients with IDH1/2 mutations may benefit from ATRA. Bout-
zen, et al.20 researched the sensitivity of leukemic cells with the 
IDH1/R132H mutation to ATRA. They noted that mutant IDH1/
R132H-specific gene features controlled by key transcription 
factors, especially CEBPα, were involved in myeloid differentia-
tion and retinoic responsiveness. Additionally, their results in-
dicated the IDH1/R132H-mutated protein and its production, 
2-HG, sensitized AML cell lines and primary AML cells for 
ATRA-induced granulocyte differentiation and apoptosis. 
Therefore, in this study, the effects of combined treatment 
with ATRA and AG-221 on differentiation and possible under-
lying mechanisms in IDH2-mutant AML were explored. 
MATERIALS AND METHODS
Cells and culture
The human AML cell line IDH2-mutant-TF-1 (TF-1/R140Q 
cells) was obtained from American Type Culture Collection 
(ATCC; Manassas, VA, USA). The IDH2-naïve AML cell line 
(TF-1 cells) was kindly provided by Dr C.H. Park (Medicinal & 
Pharmaceutical Chemistry, Korea University of Science and 
Technology, Daejeon, Korea). All cell lines were maintained in 
RPMI-1640 medium (Invitrogen Corporation, Carlsbad, CA, 
USA) supplemented with 10% heat-inactivated fetal bovine 
serum (Gibco Life Technologies, Carlsbad, CA, USA), 2 ng/mL 
of recombinant human GM-CSF (Merck KGaA, Darmstadt, Ger-
many), and 100 U/mL penicillin in 5% CO2 at 37°C. To maintain 
exponential growth, cells were seeded at 1×105 cells/ml and 
passaged every 3 days. 
Patients and isolation of AML cells
This study adhered to the tenets of the Declaration of Helsinki 
and was approved by the Institutional Review of Board of Sev-
erance Hospital. Study participants provided written informed 
consent, and all patient samples were coded and linked anon-
ymously. Identification of samples was possible using a code, 
and anonymized clinical information of linked samples was 
provided for researchers. Human leukemia cells were obtained 
from diagnostic bone marrow aspiration of patients with de 
novo AML diagnosed at Yonsei University Severance Hospi-
tal between 2006 and 2018. Mononuclear cells were isolated 
by Ficoll-Hypaque (GE Healthcare Life Sciences, Seoul, Ko-
rea) density gradient centrifugation and then cryopreserved. 
We selected four samples from AML patients with IDH2/R140Q 
mutation. 
Reagents
Stock solutions of the following reagents were prepared by dis-
solving them in dimethyl sulfoxide (Biosesang, Seongnam, 
Korea): AG-221 (Selleckchem, Seoul, Korea), ATRA (Sigma-
Aldrich, St. Louis, MO, USA), bafilomycin C1 from Streptomyces 
griseus (Sigma-Aldrich), U0126 (Sigma-Aldrich), and Sorafenib 
CSF (Merck KGaA). A stock solution of 3-methyladenine (Sig-
ma-Aldrich) was prepared by dissolving it in distilled water. 
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Control cells were treated with equal volumes of the solvent. 
Differentiation assay
Leukemic cell differentiation was evaluated according to mor-
phology with Wright’s staining and the expression of differen-
tiation antigens CD14, CD15, and CD11b. CD14, CD15, and 
CD11b were measured using fluorescein isothiocyanate (FITC)-
label anti-CD14 (BD Biosciences, Franklin Lakes, NH, USA), 
FITC-label anti-CD15 (BD Biosciences), and phycoerythrin 
(PE)-label anti-CD11b (BD Biosciences) with isotype controls 
by flow cytometry (BD FACSCalibur, Franklin Lakes, NH, USA). 
Western blot analysis
Total cell lysates were prepared and analyzed by Western blot-
ting as described previously.21 Rabbit polyclonal anti-body 
against LC3 was obtained from Novus Biologicals (Centenni-
al, CO, USA). P62/SQSTM1 was purchased from Abnova (Tai-
wan). Beclin-1 and rabbit polyclonal antibodies against phos-
pho-c-RAF (Ser259), phospho-MEK1/2 (Ser221), and phospho-
p44/42 MAPK (ERK1/2)(Thr202/Tyr204) were purchased from 
Cell Signaling Technology (Danvers, MA, USA). Bi-methyl H3K9, 
bi-methyl H3K27, and tri-methyl H3K9 antibodies were ob-
tained from Abcam (Cambridge, UK). Mouse anti-α-tubulin 
monoclonal antibodies were obtained from Merck Millipore 
(Burlington, MA, USA). Secondary antibodies were coupled to 
horseradish peroxidase and visualized by enhanced chemilu-
minescence (GE Healthcare Life Sciences, Seoul, Korea).
2-HG measurement 
A cell suspension of 1×107 leukemia cells was prepared, and 
2-HG levels were measured by 2-HG Assay Kits (Colorimetric) 
(Abcam, Cambridge, UK). We set up plates in duplicate for ex-
ternal standard (50 μL of 20 nM 2-HG), internal standard (50 
μL of 5 nM 2-HG+sample), sample (50 μL), sample background 
(50 μL), and reagent background (50 μL of buffer). Plates were 
incubated at 37°C for 60 minutes protected from light. The 
amount of 2-HG was measured on a microplate reader at op-
tical density (OD) 450 nm. 
Statistical analysis 
Results are expressed as the mean±standard deviation of at least 
three independent experiments. Comparison of two groups was 
performed using two-tailed Student’s t-test. Statistical analysis 
was performed using GraphPad Prism 4.0 (GraphPad Software 
Inc., La Jolla, CA, USA). Differences with p values of less than 
0.05 were considered statistically significant.
RESULTS
AG-221 induces differentiation of TF-1/R140Q cells
We initially examined the effects of AG-221 on differentiation 
in the IDH2-mutant AML cell line TF-1/R140Q and the IDH2-
naïve AML cell line TF-1. The TF-1/R140Q cells were derived 
from parental TF-1 cells. TF-1/R140Q and TF-1 cells were treat-
ed for 3, 5, and 7 days with increasing concentrations of AG-
221. As shown in Fig. 1A, AG-221 treatment for 7 days increased 
CD14 and CD15 expression in TF-1/R140Q cells in a dose-de-
pendent manner. Treatment with more than 50 μM AG-221 for 
5 days also increased CD14 and CD15 expression in TF-1/
R140Q cells. However, the CD14 and CD15 expression rates 
were minimal when TF-1 cells were treated with up to 50 μM 
AG-221 for 7 days. Treatment of TF-1/R140Q cells with 10 μM 
AG-221 for 5 and 7 days exhibited mature-related morpholog-
ical alterations, such as condensed chromatin and decreased 
nuclei/cytoplasm ratio with smaller nuclei (Fig. 1B). 
ATRA induces differentiation of TF-1/R140Q cells
Next, we examined whether ATRA induces differentiation of 
TF-1/R140Q cells. Treatment of IDH2/R140Q cells with ATRA 
for 7 days produced significant differentiation, as determined 
by increases in the percentages of CD14+ and CD15+ cells, in a 
dose-dependent manner (Fig. 2A). Treatment of TF-1/R140Q 
cells with 100 nM ATRA for 5 and 7 days showed alterations of 
cell morphology with mature characters (Fig. 2B). In contrast, 
treatment of ATRA in TF-1 cells did not result in differentiation 
induction, indicated by the lack of surface antigens associated 
with myeloid differentiation, including CD14 and CD15, and 
mature-related morphologic changes (Fig. 2).
Combined treatment with AG-221 and ATRA inhibits 
the production of 2-HG in TF-1/R140Q cells
As reported previously22 and consistent with observations in 
myeloblasts from patients with IDH1/2-mutant AML,15 TF-1/
R140Q cells induced intracellular 2-HG production at concen-
trations of 48.5 to 59.7 nmol/mg. However, TF-1 cells did not 
produce intracellular 2-HG. We treated the TF-1/R140Q cells 
with 30 μM AG-221 and 100 nM ATRA, alone or in combina-
tion (Fig. 3A). AG-221 induced suppression of intracellular 
2-HG levels in TF-1/R140Q cells. When cultured in the pres-
ence of 30 μM AG-221, TF-1/R140Q cells showed an approxi-
mately 81% decrease in intracellular 2-HG. ATRA treatment 
also suppressed intracellular 2-HG levels in TF-1/R140Q cells. 
TF-1/R140Q cells were more sensitive to the inhibitory action of 
AG-221 than ATRA. Decreases in intracellular 2-HG levels were 
more marked when the TF-1/R140Q cells were treated with a 
combination of AG-221 and ATRA rather than when the cells 
were treated with either AG-221 or ATRA.
Combined treatment with AG-221 and ATRA elicits 
synergistic benefits in differentiation of IDH2/R140Q 
cells and primary AML samples
In order to assess the effect of the combination therapy, we 
treated IDH2/R140Q cells with 30 μM AG-221 and 100 nM 
ATRA, alone or in combination. We treated the cells continu-
ously for 7 days. We determined the percentage of differentiated 
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cells (surface expression of myeloid marker CD14 and CD15) 
under the various treatment conditions by flow cytometry. The 
combination of 30 μM AG-221 and 100 nM ATRA induced a 
larger population of differentiated CD14+ and CD15+ cells in 
comparison to single ATRA and AG-221 treated cells after 7 
days (Fig. 3B). Cytology revealed that by day 7 of AG-221 and 
ATRA combination treatment, the blasts or myeloblasts had 
decreased, and early signs of maturation were observed by in-
creases in the number of myelocytes and metamyelocytes (Fig. 
3C). We applied the same treatment regimens to TF-1 cell lines. 
As expected, cell differentiation by the AG-221 alone was re-
duced to 27.4±3.0%, and the cells showed minimal differentia-
tion in the presence of AG-221 and ATRA combination treat-
ment. 
To investigate the effect of AG-221 and ATRA individually or 
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Fig. 1. AG-221 induces differentiation of TF-1/R140Q cells. (A) TF-1 and TF-1/R140Q cells were exposed to 1, 5, 10, and 50 μM AG-221 for the indicated 
time periods. After treatment, differentiation was assessed according to CD14 and CD15 expression by flow cytometry. (B) After treatment of TF-1 and 
TF-1/R140Q cells with 10 μM AG-221 for 5 and 7 days, cell morphology was observed under a microscope following Wright’s staining of cells that were 
collected onto slides by cytospin. 
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tient samples containing IDH2/R140Q mutation (n=4) (Table 
1). Patient bone marrow samples were sorted and cultured in 
conditioned medium either in the presence or absence of 30 
μM AG-221 and 100 nM ATRA, alone or in combination, and 
the samples of each culture were collected at 7 days. Differen-
tiation of AML blasts was evaluated by flow cytometry analy-
sis for changes in cell surface markers associated granulocytic 
differentiation (CD11b, CD14, and CD15). Treatment with 
AG-221 or ATRA induced an increase in the number of differ-
entiated cells in IDH2/R140Q patient samples. In all IDH2-mu-
tant samples, the increases in percentages for all cell surface 
markers were greater for AG-221 and ATRA combination ther-
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Fig. 2. ATRA induces differentiation of TF-1/R140Q cells. (A) TF-1 and TF-1/R140Q cells were exposed to 10, 20, 50, and 100 nM ATRA for the indicated 
time periods. After treatment, differentiation was assessed according to CD14 and CD15 expression by flow cytometry. (B) After treatment of TF-1 and 
TF-1/R140Q cells with 100 nM ATRA for 5 and 7 days, cell morphology was observed under a microscope following Wright’s staining of cells that were 
collected onto slides by cytospin. ATRA, all-trans retinoic acid.
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Combined treatment with AG-221 and ATRA alters 
autophagic activity during differentiation of IDH2/
R140Q cells
To examine alterations in autophagy-related molecules by AG-
221 and ATRA, Western blot analyses were performed on whole 
cell lysates from TF-1/R140Q and TF-1 cells collected 7 days af-
ter treatment with 30 μM AG-221 and 100 nM ATRA, alone or 
in combination. In TF-1/R140Q cells treated with AG-221 and 
ATRA, we observed an increase in the conversion of LC3-I to 
LC3-II, which is a widely accepted marker for autophagosome 
formation.23 The increase in beclin-1, another indicator for au-
tophagy initiation that participates in autophagosome forma-
tion by interacting with hVps34,24 paralleled the increased 
LC3-II levels in TF-1/R140Q cells after treatment with AG-221 
and ATRA. When 30 μM AG-221 and 100 nM ATRA was used 
in combination, the accumulation of LC3-II and beclin-1 pro-
teins were further enhanced, compared to treatment with AG-
221 or ATRA alone. In addition, p62/SQSTM1 protein interacts 
with both LC3-II and ubiquitin protein and is degraded in au-
tophagosomes. Therefore, an increase in p62/SQSTM1 would 
indicate inhibited autophagic degradation, whereas a reduction 
in p62/SQSTM1 would indicate increased autophagic degra-
dation. As shown in Fig. 4A, AG-221 and ATRA treatment failed 
to decrease the expression levels of p62/SQSTM1 protein. Col-
lectively, these results suggested that, during AG-221 and ATRA-
induced leukemic cell differentiation, autophagosome forma-
tion increases, while the degradation of autophagic vacuoles 
decreases. 
Next, we examined whether autophagy regulation contributes 
to the effects of combined treatment with AG-221 and ATRA on 
the differentiation of TF-1/R140Q cells by autophagy inhibi-
tion using pharmacological inhibitors. The addition of 3-MA 
to AG-221 and ATRA combination treatment resulted in a sig-
nificant decrease in CD14 and CD15 expression (Fig. 4B) (p= 
0.007; p=0.013), compared to treatment with AG-221 or ATRA. 
However, the addition of bafilomycin A1 to AG-221 and ATRA 
combination treatment failed to change the expression levels 

































































































































































Fig. 3. AG-221 and ATRA combined effects on differentiation of TF-1/R140Q cells and primary AML samples. (A and B), TF-1 and TF-1/R140Q cells were 
exposed to 30 μM AG-221 and 100 nM ATRA, alone or in combination, for 7 days. (A) Intracellular amounts of 2-HG determined by D-2-HG Assay Kit 
(Colorimetric). (B) After treatment, differentiation was assessed according to CD14 and CD15 expression by flow cytometry. (C) After treatment of TF-1 
and TF-1/R140Q cells with 30 μM AG-221 and 100 nM ATRA, alone or in combination, for 7 days, cell morphology was observed under a microscope fol-
lowing Wright’s staining of cells that were collected onto slides by cytospin. Differentiation of AML blasts was evaluated by flow cytometry analysis for 
changes in CD11b, CD14, and CD15 expression. p≤0.05 indicates statistical significance of the observed differences. Columns, mean values of three in-
dependent experiments for cell lines and data obtained from four primary samples; bars, standard deviations. ATRA, all-trans retinoic acid; AML, acute 
myeloid leukemia; IDH2, isocitrate dehydrogenase 2.
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Fig. 3. AG-221 and ATRA combined effects on differentiation of TF-1/R140Q cells and primary AML samples. (D) Primary AML cells with IDH2-mutant 
(n=4) were cultured in conditioned medium either in the presence or absence of 30 μM AG-221 and 100 nM ATRA, alone or in combination, and samples 
for each culture were collected on day 7. Differentiation of AML blasts was evaluated by flow cytometry analysis for changes in CD11b, CD14, and 
CD15 expression. p≤0.05 indicates statistical significance of the observed differences. Columns, mean values of three independent experiments for cell 
lines and data obtained from four primary samples; bars, standard deviations. ATRA, all-trans retinoic acid; AML, acute myeloid leukemia; IDH2, isoci-
trate dehydrogenase 2.
Table 1. Overview of Primary Human AML Cells 
Patient no. Sex IDH2 NGS Chromosome Source CD34 %
YH001 Male R140 46, XY [20] BM 96.40
YH003 Male R140 IDH2, NRAS, KMT2C, BCORL1, PHF6 47, XY, +14 [13] BM 78.73
YH024 Male R140 NPM1, IDH2, PTPN11 46, XY BM 0.39
YH034 Male R140 IDH2, NRAS, BCOR, BCORL1 46, XY BM 1.30


































































































































































































































































































































































that treatment with AG-221 or ATRA. Bafilomycin A1 is a known 
inhibitor of the late phase of autophagy, preventing the matura-
tion of autophagic vacuoles by inhibiting fusion between au-
tophagosomes and lysosomes.25 Thus, bafilomycin A1 was 
introduced to test whether autophagy deficiency affects (espe-
cially the defect of late step in autophagy) AG-221 and ATRA-
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induced differentiation. The results indicated that AG-221 and 
ATRA treatment-induced differentiation of TF-1/R140Q cells 
is associated with autophagy, without suppressing autophagy 
flux at maturation and degradation stages.
 Activation of the RAF-1/MEK/ERK pathway upon 
combined treatment with AG-221 and ATRA in IDH2/
R140Q cells
With mounting evidence indicating that ATRA-induced differ-
entiation in a variety of cell lines is dependent on MEK/ERK 
activation and with more comprehensive information of MEK/
ERK signaling in some models,26,27 we examined alterations in 
MEK/ERK signaling in AG-221 and ATRA-induced differentia-
tion in TF-1/R140Q cells. We investigated whether MEK/ERK 
was activated with AG-221 and ATRA treatment by Western 
blot analysis of phosphorylated MEK1/2 (Ser221) and phos-
phorylated ERK1/2 (Thr202/Try204). MEK was phosphorylat-
ed even in TF-1/R140Q cells without treatment. Moreover, fol-
lowing treatment with 30 μM AG-221 and 100 nM ATRA alone 
or in combination for 7 days, the amounts of phosphorylated 
MEK were increased. Meanwhile, the activation of ERK1/2 oc-
curred after 7 days by AG-221 and ATRA treatment (Fig. 5A). 
To further study whether MEK/ERK activation was necessary 
for AG-221 and ATRA-induced differentiation in TF-1/R140Q 
cells, the cells were incubated with 2 μM U0126, a specific in-
hibitor of MEK, with AG-221 and ATRA treatment. The effec-
tiveness of U0126 was evaluated by ERK1/2 phosphorylation 
with the indicated treatment for 7 days. When the activation 
of ERK 1/2 peaked after AG-221 and ATRA combination treat-
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Fig. 4. Effects of autophagy inhibition on AG-221 and ATRA-induced differentiation of TF-1/R140Q cells. TF-1 and TF-1/R14-Q cells were treated with 30 
μM AG-221 and 100 nM ATRA alone or in combination for 7 days. (A) Autophagy was measured in both cells by evaluating protein levels of LC3-I/II, 
beclin-1, and p62/SQSTM1 in whole cell lysates. α-tubulin was used as a protein-loading control. (B) TF-1 and TF-1/R140Q cells were treated for 7 
days with 30 μM AG-221 and 100 nM ATRA combination treatment or in addition of autophagy inhibitor, either 3-methyladenine (3-MA, 5 μM) or bafilo-
mycin A1 (Baf. A1, 10 μM). Inhibition of AG-221 and ATRA-induced autophagy by 3-MA or Baf. A1 was measured by Western blotting for LC3-I/II, be-
clin-1, and p62/SQSTM1 expressions. CD14 and CD15 expression by flow cytometry on day 7 was used as a marker of differentiation. p≤0.05 indicates 
statistical significance of the observed differences. ATRA, all-trans retinoic acid.
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treatment with 2 μM U0126 significantly suppressed CD14 and 
CD15 expression (Fig. 5B) (p=0.008; p=0.006). These results 
highlighted the role of the MEK/ERK signal pathway in the dif-
ferentiation-inducing effects of AG-221 and ATRA in TF-1/
R140Q cells. To investigate the upstream molecules in the 
MEK/ERK signal pathway involved in AG-221 and ATRA-in-
duced differentiation of TF-1/R140Q cells, we assessed RAF-1, 
a classical upstream regulator of the MEK/ERK signal path-
way. The activation of RAF-1 by AG-221 and ATRA was ana-
lyzed by Western blot of Phospho-c-Raf (Ser259). RAF-1 was 
phosphorylated even in TF-1/R140Q cells without treatment. 
The phosphorylation of RAF-1 at Ser338 was not increased 
with AG-221 and ATRA treatment (Fig. 5A). To further investi-
gate whether RAF-1 activation was required for MEK/ERK sig-
naling, cells were co-treated with 2.5 μM sorafenib tosylate, a 
specific inhibitor of RAF-1. The inhibitory effect of sorafenib 
tosylate on RAF-1 activation was evaluated by phosphoryla-
tion of MEK1/2, as well as ERK1/2, with the indicated treat-
ments for 7 days. The phosphorylation of MEK1/2 ERK1/2 
upon combined treatment with AG-221 and ATRA for 7 days 
was decreased by sorafenib tosylate co-treatment (Fig. 5B). 
Thus, the activation of MEK/ERK by AG-221 and ATRA was 
deemed to be dependent on RAF-1. Moreover, 2 μM sorafenib 
tosylate also attenuated AG-221 and ATRA-induced differenti-
ation, as assessed by CD14 and CD15 expression (p=0.012; p= 
0.013) (Fig. 5B). These results demonstrated the involvement 
of RAF-1/MEK/ERK in AG-221 and ATRA-induced differenti-
ation in TF-1/R140Q cells. 
Combined treatment with AG-221 and ATRA alters 
isocitrate dehydrogenase-associated changes in 
histone methylation
Studies have demonstrated that 2-HG-producing IDH mutants 
can prevent histone demethylation, which is required for lin-
eage-specific progenitor cells to differentiate into terminally 
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Fig. 5. Activation of RAF-1/MEK/ERK on AG-221 and ATRA-induced differentiation of TF-1/R140Q cells. (A) The activation of RAF-1/MEK/ERK signaling 
was evaluated by Western blot analysis of the phosphorylation status of MEK1/2, ERK1/2, and c-Raf in TF-1 and TF-1/R140Q cells treated with 30 μM 
AG-221 and 100 nM ATRA for 7 days. α-tubulin was used as a protein-loading control. (B) Cells were co-treated with either 2 μM U0126 or 2.5 μM 
sorafenib, and AG-221 and ATRA-induced differentiation for 7 days was evaluated by flow cytometry using CD14 and CD15 expressions. p≤0.05 indi-
cates statistical significance of the observed differences. ATRA, all-trans retinoic acid.
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tion is dysregulated in IDH2-mutant AML, Western blot anal-
ysis of TF-1/R140Q and TF-1 cells was performed for well-
characterized histone markers. Compared to IDH2-naïve AML 
cells, we noted an increase in the repressive trimethylation of 
H3K9 (H3K9me3) and no significant difference in biomethyl-
ation of H3K27 (H3K27me2) and H3K9 (H3K9me2) in IDH2-
mutant AML cells (Fig. 6). To further study whether the induc-
tion of differentiation by AG-221 and ATRA treatment alters 
histone methylation markers, Western blot analysis of histone 
methylation markers was performed on whole cell lysates 
from TF-1/R140Q collected 7 days after treatment with 30 μM 
AG-221 and 100 nM ATRA alone or in combination. H3K9me3, 
H3K9me2, and H3K27me2 proteins were decreased signifi-
cantly only after combined treatment with AG-221 and ATRA 
(Fig. 6). 
DISCUSSION
Although IDH2 inhibitor, such as AG-221, has shown early 
success in AML,28 not all patients experience clinical benefits. 
It is expected that for more powerful responses, differentiation-
based IDH2 inhibition will need to be combined with other 
treatment modalities, such as standard chemotherapy, or other 
types of mechanism-based target therapy.19 This study showed 
that combination therapy, specifically AG-221 and ATRA, in 
IDH2-mutant AML achieves therapeutic efficacy through in-
duction of differentiation. 
Previous studies have shown that AG-221 results in differ-
entiation in IDH2-mutant TF-1 cells and primary AML cells ex 
vivo, as well as in IDH2/R140Q mutant AML xenograft mouse 
models in vivo, and have reported a survival benefit in an in vivo 
AML xenograft model.29 Our findings confirm the AG-221 
causes differentiation of IDH2-mutant AML cells, as demon-
strated by changes in morphology and myeloid-related anti-
gens. AG-221 is a first-in-class inhibitor of the mutant IDH2 en-
zyme. AG-221 binds to an allosteric site within the dimer link, 
stabilizing the open configuration of the enzyme and inhibit-
ing the change of α-ketoglutarate to 2-HG. AG-221 exhibits 
excellent pharmaceutical characteristics, including proper sol-
ubility, low clearance, and good oral bioavailability, and power-
fully inhibits 2-HG production by both the IDH2/R140Q-WT 
heterodimer and IDH2/R140Q homodimer.29 Our data indicat-
ed that in IDH2-mutant AML cells, IDH2/R140Q expression in 
the TF-1 erythroleukemia cell line produced intracellular 2-HG 
and that 2-HG levels were decreased by AG-221 treatment. 
Although sustained efforts are being made to successfully 
combine IDH2 inhibitors with chemotherapy,30 we also now 
have a better understanding of the molecular changes of spe-
cific pathways that frequently occur in AML. Therefore, the in-
vestigation of further targeted therapeutic agents that may syn-
ergize with IDH2 inhibition could move clinical trials toward 
the goal of eliminating chemotherapy altogether. Here, ATRA 
has been shown to act synergistically with IDH2 inhibitor-in-
duced differentiation in IDH2 mutant AML cells and primary 
AML cells, compared with either drug alone. The enhanced ef-
fectiveness of AG-221 and ATRA combination treatment in in-
ducing differentiation was most evident after 7 days of treat-
ment in IDH2-mutant AML cells. 
Autophagy plays an intrinsic role as an protein turnover in 
mammalian development and differentiation.31,32 Within the 
hematopoietic system, autophagy plays a vital role in organelle 
clearance during reticulocyte differentiation,32 lymphocyte dif-
ferentiation32 and plasma cell differentiation,33 indicating that 
autophagy may also be essential for normal myeloid differen-
tiation. Autophagy is increased during ATRA-induced granulo-
cytic differentiation of the APL cell line, and this is linked with 
increased expression of LC3II and GATE-16 proteins involved 
in autophagosome formation. Autophagy inhibition attenu-
ates myeloid differentiation.34 Consistent with this finding, 
AG-221 and ATRA combination treatment was found to alter 
autophagic activity in a manner of considerable accumulation 
of autophagosomes without an increase in the degradation of 
autophagic vacuoles, as assessed by the elevation of LC3-II and 
beclin-1 protein levels, as well as no significant decrease of p62/
SQSMT1. Autophagy inhibition using a pharmacological inhibi-
tor resulted in a decrease of AG-221 and ATRA-induced differ-
entiation in IDH2-mutant AML cells. However, a decrease in 
AG-221 and ATRA-induced differentiation following cotreat-
ment with the autophagic degradation inhibitor bafilomycin 
A1 in IDH2-mutant AML cells was not observed. Taken togeth-
er, the results indicated that AG-221 and ATRA treatment-in-
duced differentiation of IDH2-mutant AML cells was associat-
ed with autophagy induction, without suppressing autophagy 
flux at maturation and degradation stages. 
Recently, RAF-1/MEK/ERK cascade has been reported to be 
associated with ATRA-induced differentiation in APL cells.35 
Consistent with this finding, MEK/ERK activation after AG-
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Fig. 6. Decreases in histone methylation after AG-221 and ATRA combi-
nation treatment. TF-1 and TF-1/R140Q cells were treated with 30 μM 
AG-221 and 100 nM ATRA alone or in combination for 7 days. TF-1 and 
TF-1/R140Q cells were assessed for expression levels of histone meth-
ylation by Western blot with specific antibodies. α-tubulin was used as 
a protein-loading control. Similar results were obtained in three inde-
pendent experiments. ATRA, all-trans retinoic acid.
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through MEK1/2 (Ser221) and ERK1/2 (Thr202/Tyr204) phos-
phorylation in IDH2-mutant AML cells. The role of MEK/ERK 
activation in AG-221 and ATRA-induced differentiation was 
shown by targeting MEK with a pharmacologic inhibitor. MEK 
inhibition reduced AG-221 and ATRA-induced differentiation 
of IDH2-mutant AML cells. To investigate the upstream regu-
lators of MEK/ERK, RAF-1 was selected. Similar to MEK acti-
vation, the phosphorylation of RAF-1 at Ser259 was found and 
continued with AG-221 and ATRA treatment. The inhibition of 
RAF-1 promoted MEK/ERK inhibition and decreased AG-221 
and ATRA-induced differentiation in IDH2-mutant AML cells. 
This suggested that RAF-1 is a positive upstream regulator of 
the MEK/ERK signal pathway involved in AG-221 and ATRA-
induced differentiation in IDH2-mutant AML cells. Indeed, re-
search has shown that RAF-1 is an upstream molecule of MEK/
ERK and that RAF-1/MEK/ERK cascade participates in ATRA-
triggered differentiation in HL-60 cells.36
A recent study reported that IDH mutation worsens histone 
demethylation and blocks cell differentiation.16 In the present 
study, we discovered a marked increase in the histone marker 
H3K9me3 in IDH2-mutant AML cells, compared with IDH2-
WT AML cells. Meanwhile, biochemical studies have suggested 
that 2-HG is a universal inhibitor of Jumonji-C domain histone 
demethylase (JHDM) family members.37 Future investigation 
of sensitivity to 2-HG inhibition among JHDM family members 
and/or cellular feedback mechanisms promoted after faulty 
histone demethylation will be needed. 
This study showed that ATRA enhances IDH2 inhibitor-in-
duced differentiation in IDH2-mutant AML cells. These results 
suggest that combining IDH2 inhibition with ATRA treatment 
would likely be minimal cytotoxic to normal cells and would 
be well tolerated by older AML patients, giving at least tran-
sient disease control in the absence of cytotoxic chemotherapy. 
Furthermore, we provide preliminary evidence that the addi-
tion of ATRA may lead to further improvements or increases 
in response rates to treatment with IDH2 inhibitor in IDH2-
mutant AML patients who show no benefits from them other-
wise. Our results indicate that autophagy is a vital component 
of the influence of AG-221 and ATRA on differentiation in IDH2 
mutant AML and that pharmacologic autophagy regulation is 
this context may potentiate the AG-221 and ATRA-induced dif-
ferentiation of IDH2-mutant AML cells. The definitive mecha-
nisms through which AG-221 and ATRA activate autophagy 
remain to be explained. Further studies will address this issue 
so that we can understand how best to target this process for 
patient benefits. The present results further demonstrated that 
the induction of differentiation by AG-221 and ATRA requires 
the activation of RAF-1/MEK/ERK cascades. Considering the 
complex mechanisms involved in the activation of the RAF/
MAK/ERK pathway, further studies will need to be performed 
to better understand the effect of AG-221 and ATRA-induced 
activation of MEK/ERK kinases, and the identification of more 
downstream targets of the MEK/ERK signal pathway in this cell 
model might be crucial to explain its translational role. 
Although all of the events responsible for AG-221 and ATRA-
induced differentiation in IDH2-mutant AML cells have not 
yet been elucidated, we discovered that combining IDH2 inhi-
bition with ATRA treatment may be useful for inducing the dif-
ferentiation of leukemia cells, thereby providing improved ther-
apeutic responses in AML patients.
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